Verona Pharma is engaged in the research, discovery and development of drugs for the treatment of allergic rhinitis (hay fever) and other chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), as well as chronic inflammatory diseases.
Verona Pharma provides value and opportunity to investors through:
Strong Patent Protection: The drug candidates under development by Verona Pharma are backed by strong patent protection.
Multi-Million Dollar Market Opportunities: Verona Pharma's drug candidates are targeting multi-million dollar global markets.
Virtual R&D Model: The Company's outsourcing model reduces the need for a large specialized workforce and investment in physical infrastructure and allows access to the resources and facilities of well-established academic institutions.
Rapid and cost-effective drug development: Verona Pharma drug development programmes have a relatively rapid and low cost route to market.
R&D Pipeline for Continued Growth: Verona Pharma's scientists are working on developing new potential drug candidates for the treatment of respiratory and inflammatory diseases.
Experienced Board and Management Team: Verona Pharma's management is backed by a strong Board of Directors, Scientific Advisory Panel and industry partners.
